[
    [
        {
            "time": "2018-03-15",
            "original_text": "Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study",
            "features": {
                "keywords": [
                    "Opdivo",
                    "Yervoy",
                    "Combo",
                    "Positive",
                    "Cancer",
                    "Study"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill",
            "features": {
                "keywords": [
                    "diabetes",
                    "Novo Nordisk",
                    "new pill"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-06",
            "original_text": "Free Post Earnings Research Report: AbbVie’s Q4 FY17 Results Beat Market Estimates",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Q4",
                    "FY17",
                    "Results",
                    "Beat",
                    "Market Estimates"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Free Post Earnings Research Report: AbbVie’s Q4 FY17 Results Beat Market Estimates",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]